Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06440473 · ClinicalTrials.gov registry record · Phase 4
Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin
A Phase 4 study of Healthy Skin, sponsored by Rao Dermatology.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT06440473 is a Phase 4 study of Healthy Skin that is actively recruiting participants, run by Rao Dermatology. The registered enrollment target is 3 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06440473, a Phase 4 study of Healthy Skin, is actively recruiting participants, sponsored by Rao Dermatology.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to visualize the deposition of topical 0.3% roflumilast (Zoryve) compared to vehicle using Line-Field Optical Coherence Tomography (LC-OCT) in vivo in healthy skin. We hypothesize that the application of topical 0.3% roflumilast (Zoryve) will result in distinct patterns of deposition within the epidermal and dermal layers compared to the vehicle. Specifically, we anticipate observing deeper penetration and more uniform distribution of roflumilast within the skin layers, indicative of enhanced efficacy, as visualized by LC-OCT imaging.
Conditions Studied
Interventions
- DRUG Roflumilast
- OTHER Vehicle (Roflumilast 0.3% vehicle cream)
Study Locations (1)
New Jersey
- Rao Dermatology - Atlantic Highlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-05-28 |
| Est. Completion | 2024-07-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06440473
The ClinicalTrials.gov registry entry for NCT06440473 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rao Dermatology, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Skin appearing as the primary indexed condition, and to 2 interventions - of which Roflumilast is the first listed.
NCT06440473 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06440473 about?
NCT06440473 is a clinical study titled "Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin". The goal of this study is to visualize the deposition of topical 0.3% roflumilast (Zoryve) compared to vehicle using Line-Field Optical Coherence Tomography (LC-OCT) in vivo in healthy skin. We hypothesize that the application of topical 0.3% roflumilast (Zoryve) will result in distinct patterns of ...
What is the current status of trial NCT06440473?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2024-05-28. Estimated completion is 2024-07-28.
What conditions does trial NCT06440473 study?
This clinical trial studies the following conditions: Healthy Skin.
What interventions are being tested in trial NCT06440473?
The interventions under investigation include: Roflumilast (DRUG), Vehicle (Roflumilast 0.3% vehicle cream) (OTHER).
Who is sponsoring clinical trial NCT06440473?
This trial is sponsored by Rao Dermatology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06440473 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Skin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.